Dermata Therapeutics Inc DRMA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.76 up $0.00, 0.28% at close Nov 6
Last close · Previous close $0.76
- Market cap
- At the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$0.76down $0.37, 32.39%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.76Nov 5
- Volume60.21KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume8.39MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.60 to $4.66; now $0.76
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
DRMA trailed the S&P 500 in all 6 periods.
| Period | DRMA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | DRMA: down 32.4% S&P 500: down 5.6% | DRMA trailed the S&P 500 by 26.8 percentage points Trailed |
| 3M | DRMA: down 31.2% S&P 500: down 4.1% | DRMA trailed the S&P 500 by 27.1 percentage points Trailed |
| YTD | DRMA: down 67.1% S&P 500: up 8.7% | DRMA trailed the S&P 500 by 75.8 percentage points Trailed |
| 1Y | DRMA: down 74.1% S&P 500: up 10.9% | DRMA trailed the S&P 500 by 85.0 percentage points Trailed |
| Long term | ||
| 3Y | DRMA: down 99.4% S&P 500: up 75.0% −81.7% vs +20.5% a year | DRMA trailed the S&P 500 by 174.4 percentage points Trailed |
| 5Y | DRMA: down 100.0% S&P 500: up 67.8% −85.9% vs +10.9% a year | DRMA trailed the S&P 500 by 167.8 percentage points Trailed |
$10,000 invested in DRMA 5 years ago (Nov 5, 2021) would be worth about $1 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
DRMA trailed the S&P 500 in all 6 periods.
| Period | DRMA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | DRMA: down 32.4% S&P 500: down 5.6% | DRMA trailed the S&P 500 by 26.8 percentage points Trailed |
| 3M | DRMA: down 31.2% S&P 500: down 4.3% | DRMA trailed the S&P 500 by 26.9 percentage points Trailed |
| YTD | DRMA: down 67.1% S&P 500: up 7.8% | DRMA trailed the S&P 500 by 74.9 percentage points Trailed |
| 1Y | DRMA: down 74.1% S&P 500: up 9.7% | DRMA trailed the S&P 500 by 83.8 percentage points Trailed |
| Long term | ||
| 3Y | DRMA: down 99.4% S&P 500: up 68.8% −81.7% vs +19.1% a year | DRMA trailed the S&P 500 by 168.2 percentage points Trailed |
| 5Y | DRMA: down 100.0% S&P 500: up 56.9% −85.9% vs +9.4% a year | DRMA trailed the S&P 500 by 156.9 percentage points Trailed |
$10,000 invested in DRMA 5 years ago (Nov 5, 2021) would be worth about $1 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$15,000.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Aug 13, 2021.
Stock splits
3
Latest: 1-for-10 on . Share counts adjust after each split.
All 3 splits
- 1-for-10
- 1-for-15
- 1-for-16
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$8.37M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$3.17M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$3.15M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$2.30M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$1.70M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$1.69M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$1.86M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$1.85M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$2.97M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$7.90M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$9.61M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $0.00 | −$7.79M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$12.29M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $0.00 | −$7.56M | Paused See the note under the price. |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$8.03MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$8.03MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $6.17MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $4.41MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$0.00As of Jun 30, 2026
- Net cash$4.41MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −166.7%Last 12 months
Over the last 12 months, Dermata Therapeutics lost money: its net loss was 166.7% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −130.1%Last 12 months
Over the last 12 months, Dermata Therapeutics’s net loss was 130.1% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Dermata Therapeutics Inc
Dermata Therapeutics Inc
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
DRMA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
DRMA stock FAQ
What is DRMA stock’s price today?
Dermata Therapeutics (DRMA) traded at $0.76 at the close on , unchanged from the previous close of $0.76. Over the past 52 weeks it has traded between $0.60 and $4.66.
If you invested $1,000 in DRMA 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in DRMA on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $259 if invested one year ago. Past performance doesn’t predict future returns.
Does DRMA pay a dividend?
Dermata Therapeutics hasn’t paid a dividend in the last twelve months.
What is DRMA’s 52-week high and low?
Over the past 52 weeks DRMA has traded as low as $0.60 and as high as $4.66. At $0.76 at the close on , it is 83.6% below that high and 26.7% above the low.
What is DRMA’s all-time high?
DRMA’s highest closing price was $15,000.00 on , adjusted for stock splits. At $0.76 at the close on , it is 100.0% below that record.
Has DRMA stock ever split?
Yes, three times: 1-for-16 on ; 1-for-15 on ; 1-for-10 on .
How has DRMA stock performed?
Including dividends and measured to the close on , DRMA has returned −67.1% so far this year and −74.1% over the past year, and −100.0% over five years (−85.9% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Dermata Therapeutics in?
Dermata Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does DRMA trade on?
Dermata Therapeutics trades on the Nasdaq under the ticker symbol DRMA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.